Company / FCF Margin
Sarepta Therapeutics FCF Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-14.0%
FY2025
5-year range
-68.6% / 4.7%
FY2021-FY2025
Trend
+22.4%
vs FY2024
Sector context
#70 of 134
Health Care
What the data says
At -14.0%, Sarepta Therapeutics's fcf margin ranks #70 of 134 in the Health Care sector. FCF Margin has fluctuated over the past 10 years, ranging from -4633.1% in FY2016 to 4.7% in FY2022.
Based on SEC 10-K filings.
-14.0% in FY2025 with a 5-year CAGR of +135.4%.
Improved from -46.4% to -14.0% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- -18.7pp
- 5-Year Change
- +135.4pp
- 10-Year Change
- -
Sector benchmark
#70 of 134 in Health CareTop 52% of 134This company -14.0% Sector average -637.8%
▼
+97.8% above sector average
Key checks
Key Insights
- In FY2025, fcf margin increased 22.4% year-over-year.
- Currently 623.8pp above the Health Care sector average.
- Peak fcf margin was recorded in FY2022.
- Lowest fcf margin in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -14.0% | +22.4% |
| FY2024 | -18.0% | +61.2% |
| FY2023 | -46.4% | -1091.9% |
| FY2022 | 4.7% | +106.8% |
| FY2021 | -68.6% | +54.1% |
| FY2020 | -149.4% | +5.3% |
| FY2019 | -157.8% | -5.6% |
| FY2018 | -149.4% | +5.3% |
| FY2017 | -157.8% | +96.6% |
| FY2016 | -4633.1% | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026